Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 77

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 77
---
 to exploit patents from time to time (including patents registered solely in our name                                 
 or our affiliates’ name or in the joint names of us or an affiliate and a third party or patents which are licensed to us) is and     
 will be sufficient to protect our core intellectual property rights against third parties, our commercial activities from competition 
 or to support comprehensively our ability to develop and market our proposed products either now or in the future;                    |

| • | the lack of any particular patents or rights to exploit any particular patents, and the scope of our patents,                              
 will not have a material adverse effect on our ability to develop and market our proposed product candidates, either now or in the future; |

| • | we have or will have the resources to pursue any infringer of: (i) patents registered in our name (whether                                         
 solely or jointly with a third party) from time to time; or (ii) patents licensed to us where we or an affiliate have the financial responsibility 
 to bring such infringement actions pursuant to the relevant license agreement;                                                                     |

| • | we will develop technologies or product candidates which are patentable, either alone or in conjunction 
 with third parties;                                                                                     |

| • | the ownership, scope or validity of any patents registered in our name (either solely or jointly) from                                  
 time to time will not be challenged by third parties, including parties with whom we, or any affiliate, have entered into collaboration 
 projects or co-ownership arrangements and that any such challenge will not be successful;                                               |

| 39 |

| • | any patent or patent application owned solely or jointly by us will not be challenged on grounds that                                         
 we failed to identify the correct inventors or that we failed to comply with our duty of disclosure to the United States Patent and Trademark 
 Office or any equivalent office in a foreign jurisdiction having a disclosure requirement;                                                    |

| • | any issued patent in our sole or joint name from time to time will not be challenged in one or more post-grant                    
 proceedings, including but not limited to inter partes review, derivation proceedings, interferences, and that like; and that any 
 such challenge will not result in a complete or partial loss of rights to such issued patent or patents;                          |

| • | any patent applications in our sole or joint name from time to time will not be opposed by any third party,            
 including parties to collaboration, co-existence and any other contractual relationship with us or any of its members; |

| • | the license